Monitor for follow-up filings or commentary, coordinated C-suite selling may signal lack of confidence, especially if not part of a pre-arranged plan. Check for 10b5-1 plans in future disclosures.
ARVN drugs
ARVN drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 23 $12.30entry
- T+1 · 9mo ago +0.57%α −0.17% · $12.37
- T+5 · 9mo ago +8.86%α +8.24% · $13.39
- T+20 · 8mo ago −16.10%α −12.15% · $10.32
- T+60 · 6mo ago −28.62%α −36.87% · $8.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives at Arvinas, including the CEO, Chief Scientific Officer, and Chief Accounting Officer, each sold approximately 1,038 shares in a coordinated open-market transaction on February 23, 2026, totaling $38,717 in sales. This represents a rare instance of multiple C-suite executives selling shares simultaneously, suggesting a shared motivation such as portfolio diversification or liquidity needs.
Key Financial Metrics
Key Facts
- CEO Randy Teel sold 1,038 shares for $12,622.08
- Chief Scientific Officer Angela Cacace sold 1,038 shares for $12,622.08
- Chief Accounting Officer David Loomis sold 1,108 shares for $13,473.28
- All sales occurred on the same day at $12.16 per share
- Total insider selling cluster: $38,717 across 3 executives
Financial Impact
$38,717 in insider sales over one day
Risk Factors
- Perceived negative signal from multiple executives selling at once
- Potential misinterpretation if sales were pre-planned under 10b5-1
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (3 trades, 7d window) | cluster-ARVN-1772109077022 |
Track record
21 reports on ARVN
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +27.06% at T+20 after the May 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
- Nov 3, 202613d ago 8-K Bearish 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
- Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
- Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
- Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
- May 12, 202626w ago 8-K Mixed 6/10 No price data
- May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
- May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
- May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers